Treatment Method

Abstract

A treatment composition for treating or preventing bovine mastitis, the treatment composition characterised in that it includes at least two components which have an isoelectric point of or above substantially 6.8 and is extracted from milk, or a milk derived substance.

1 - 52 . (canceled) 
     
     
         53 . A treatment formulation for the treatment or prevention of microbial infection which includes a treatment composition extracted from whole milk, processed milk or a milk-derived substance, wherein the composition contains a cationic fraction which includes any components of the whole milk, processed milk or milk-derived substance with an isoelectric point of or greater than substantially 6.8. 
     
     
         54 . The treatment formulation of  claim 53  wherein the cationic fraction includes all components of the whole milk, processed milk or milk-derived substance with an isoelectric point of or greater than substantially 6.8. 
     
     
         55 . The treatment formulation of  claim 53  wherein the formulation includes one or more of the following:
 1. a peroxidase substrate, such as sodium thiocyanate, and/or 
 2. hydrogen peroxide or a source of hydrogen peroxide, such as ascorbate or ascorbic acid. 
 
     
     
         56 . The treatment formulation of  claim 53  wherein the treatment composition includes chitinase-like protein (CLP-1). 
     
     
         57 . The treatment formulation of  claim 53  wherein the formulation includes a cell lysing substance. 
     
     
         58 . The treatment formulation of  claim 53  wherein the treatment composition includes at least lactoferrin, lactoperoxidase and angiogenin. 
     
     
         59 . The treatment formulation of  claims 53  wherein the treatment composition includes a mixture of cationic peptides. 
     
     
         60 . The treatment formulation of  claim 53  wherein the treatment composition includes one or more of the following: N-acetyl glucosaminidase, serum amyloid A, β defensin, lysozyme, at least one immunoglobulin or at least one growth factor. 
     
     
         61 . The treatment formulation of  claim 53  wherein at least part of the treatment composition is extracted “on-farm”, during or directly after the milking process. 
     
     
         62 . A medicament formed from the treatment formulation as claimed in  claim 53  which includes one or more of the following: antibiotics, analgesics, carriers, buffers, preservatives, excipients, controlled release components, hardening or any other pharmaceutically acceptable component. 
     
     
         63 . A method of treating or preventing microbial infection using the treatment formulation as claimed in claim  1 , the method comprising applying the treatment formulation into or onto the infection site. 
     
     
         64 . A treatment formulation for the treatment or prevention of bovine mastitis which includes a treatment composition extracted from whole milk, processed milk or a milk-derived substance, wherein the composition contains a cationic fraction which includes any components of the whole milk, processed milk or milk-derived substance with an isoelectric point of or greater than substantially 6.8. 
     
     
         65 . The treatment formulation of  claim 64  that includes a cell lysing substance. 
     
     
         66 . The treatment formulation of  claim 64  wherein the formulation includes one or more of the following:
 1. a peroxidase substrate, such as sodium thiocyanate, and/or 
 2. hydrogen peroxide or a source of hydrogen peroxide, such as ascorbate or ascorbic acid. 
 
     
     
         67 . The treatment formulation of  claim 64  wherein the treatment composition includes chitinase-like protein (CLP-1). 
     
     
         68 . The treatment formulation of  claim 65  wherein the cell lysing substance is monoglyceride. 
     
     
         69 . The treatment formulation of  claim 64  wherein the treatment composition includes at least lactoferrin, lactoperoxidase and angiogenin. 
     
     
         70 . The treatment formulation of  claim 64  that includes a mixture of cationic peptides. 
     
     
         71 . The treatment formulation of  claim 64  that includes one or more of the following: N-acetyl glucosaminidase, serum amyloid A, β defensin, lysozyme, at least one immunoglobulin or at least one growth factor. 
     
     
         72 . The treatment formulation of  claim 64  wherein at least part of the treatment composition is extracted “on-farm”, during or directly after the milking process. 
     
     
         73 . A medicament, such as a teat seal, teat spray, teat wipe, udder/teat wash, milking cluster backflush solution or intramammary formulation, formed from the treatment formulation as claimed in  claim 64  and which may include one or more of the following: antibiotics, analgesics, carriers, buffers, preservatives, excipients, controlled release components, hardening or any other pharmaceutically acceptable component. 
     
     
         74 . A method treating or preventing bovine mastitis using a treatment formulation as claimed in  claim 64 , the method comprising applying the treatment formulation, medicament or item into or onto a bovine teat.